Paroxetine: Safety and tolerability issues

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 783-794

  Marks, David M ^a   Park, Min Hyeon ^b   Ham, Byung Joo ^c   Han, Changsu ^a,d   Patkar, Ashwin A ^a   Masand, Prakash S ^a   Pae, Chi Un ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Hallym University Medical Center   (South Korea)

^d Korea University   (South Korea)

Author keywords

Newer antidepressants; Paroxetine; Paroxetine safety; Selective serotonin re uptake inhibitor; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ATOMOXETINE; CIMETIDINE; CLOMIPRAMINE; CYTOCHROME P450 2D6; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; PIMOZIDE; PLACEBO; RISPERIDONE; SEROTONIN; SEROTONIN TRANSPORTER; SERTRALINE; THIORIDAZINE;

ABDOMINAL PAIN; AGITATION; ANORGASMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BINDING AFFINITY; BLEEDING; CARDIOVASCULAR MALFORMATION; CHILD HEALTH CARE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ENZYME INHIBITION; GENERALIZED ANXIETY DISORDER; GYNECOLOGIC DISEASE; HEADACHE; HUMAN; HYPERKINESIA; INFECTION; INHIBITION KINETICS; INJURY; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; MALE GENITAL SYSTEM DISEASE; MAXIMUM PLASMA CONCENTRATION; METHODOLOGY; NAUSEA; NERVOUSNESS; NEUROSIS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINITIS; RISK BENEFIT ANALYSIS; SEDATION; SEROTONIN SYNDROME; SEROTONIN UPTAKE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SUICIDAL BEHAVIOR; SWEATING; TACHYCARDIA; TERATOGENICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; VISUAL DISORDER; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA; YAWNING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CHILD; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; MENTAL DISORDERS; PAROXETINE; PREGNANCY; SEROTONIN UPTAKE INHIBITORS;

EID: 57049138975     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802423168     Document Type: Article

References (85)

1. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 200 1;7(1):25-47
2. Pae CU, Patkar AA. Paroxetine: current status in psychiatry. Expert Rev Neurother 2007;7(2):107-20
3. Bang LM, Keating GM. Paroxetine controlled release. CNS Drugs 2004;18(6):355-64; discussion 365-6
4. Heydorn WE. Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders. Expert Opin Investig Drugs 1999;8(4):417-41
5. Greb WH, Brett MA, Buscher G, et al. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiatr Scand Suppl 1989;350:99-101
6. Wagstaff AJ, Cheer SM, Matheson AJ, et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002;62(4):655-703
7. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75
8. Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998;55(1):85-120
9. Einarson A, Koren G. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations. Can Fam Physician 2006;52:593-4
10. Owens MJ, Krulewicz S, Simon JS, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 2008. [Epub ahead of print]
11. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40(2):288-95
12. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987;93(2):193-200
13. Warrington SJ, Lewis Y. Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. Int Clin Psychopharmacol 1992;6(Suppl 4):59-64
14. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25(1):119-42
15. Bell C, Wilson S, Rich A, et al. Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology (Berl) 2003;166(2):102-10
16. Pearlstein TB, Bellew KM, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial prim care companion. J Clin Psychiatry 2005;7(2):53-60
17. Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193(2):352-60
18. Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63(7):577-84
19. Dunner DL, Lipschitz A, Pitts CD, Davies JT. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin Ther 2005;27(12):1901-11
20. Gutman DA, Owens MJ. Serotonin and norepinephrine transporter binding profile of SSRIs. Essent Psychopharmacol 2006;7(1):35-41
21. Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996;42(6):757-63
22. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16(5):356-62
23. Stahl MM, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective scrotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997;53(3-4):163-9
24. Himei A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 2006;20(8):665-72
25. Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006;67(Suppl 4):27-30
26. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61 (Suppl 2):10-2
27. Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 2004;65(3):405-13
28. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19(1):67-85
29. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders - III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12(3 Suppl B):S55-87
30. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17(2):65-9
31. GlaxoSmithKline. Paxil; 2006
32. GlaxoSmithKline. Paxil CR; 2006
33. EPIP083. Available from: hrtp://ctr.gsk.co.uk/Summary/paroxetine/ epip083part2.pdf [Access date 14 June 2006]
34. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21(3):221-2
35. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007;29(5):918-26
36. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279(8):609-10
37. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55(7):503-8
38. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14(12):823-7
39. Einarson A, Pistelli A, Desantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165(6):749-52
40. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80(1):18-27
41. Sanz EJ, De-Las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365(9458):482-7
42. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160(2):173-6
43. Cohen L. The FDA advisory on paroxetine. ObGyn News 2006;41:10
44. Patkar AA, Bilal L, Masand PS. Pharmacotherapy of depression in pregnancy. Ann Clin Psychiatry 2004;16:87-100
45. Wagner KD. Paroxetine treatment of mood and anxiety disorders in children and adolescents. Psychopharmacol Bull 2003;37(Suppl 1):167-75
46. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40(7):762-72
47. Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004;43(11):1387-96
48. Wagner BM, Wong SA, Jobes DA. Mental health professionals' determinations of adolescent suicide attempts. Suicide Life Threat Behav 2002;32(3):284-300
49. FDA. Statement on recommendations of the Psychopharmacologic Drugs and Pediatric Advisory Committees. 16 September 2004. Available from: http://www.fda.gov/bbs/topics/news/2004/new01116.html [Last accessed 15 May 2008]
50. FDA. Clinical review: relationship between antidepressant drugs and suicidality in adults. Rockville, Md, Food and Drug Administration, Center for Drug Evaluation and Research, 17 Nov 2006. Available from: http://wwwfdagov/ohrms/dockets/ac/06/briefing/2006-4272bl-01-FDApdf [Last accessed 15 May 2008]
51. Hammad TA. Review and evaluation of clinical data. Washington, DC, Food and Drug Administration, 16 August 2004. Available from: http://wwwfdagov/ohrms/dockets/ac/04/briefing/ 2004-4065bl-10-TAB08-Hammads-Reviewpdf
52. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164(9):1356-63
53. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297(15):1683-96
54. Bourin M. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review. Hum Psychopharmacol 2003;18(3):185-90
55. Reynolds CF III. Paroxetine treatment of depression in late life. Psychopharmacol Bull 2003;37(Suppl 1):123-34
56. Ghose K. Tolerance and side-effects of paroxetine in elderly depressed patients. Arch Gerontol Geriatr 1997;24(1):35-45
57. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 2001;18(5):355-68
58. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13(2):100-08
59. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 1997;46(3):191-217
60. HPG2-250/85. Available from: http://ctr.gsk.co.uk/summary/paroxetine/ studylist.asp
61. Dunner DL, Cohn JB, Walshe T III, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992;53(Suppl):57-60
62. Guillibert E, Pelicier Y, Archambault JC, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl 1989;350:132-4
63. Geretsegger C, Stuppaeck CH, Mair M, et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology (Berl) 1995;119(3):277-81
64. Mulsant BH, Pollock BG, Nebes RD, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999;60(Suppl 20):16-20
65. Trivedi MH, Pigotti TA, Perera P, et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65(10):1356-64
66. Cassano GB, Puca F, Scapicchio PL, Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002;63(5):396-402
67. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with to major depression. J Clin Psychopharmacol 1993;13(6 Suppl 2):S34-9
68. Budman CL, Sherling M, Bruun RD. Combined pharmacotherapy risk. J Am Acad Child Adolesc Psychiatry 1995;34(3):263-4
69. Rahme E, Dasgupra K, Turecki G, et al. Risks of suicide and poisoning among elderly patients prescribed selective serotonin reuptake inhibitors: a retrospective cohort study. J Clin Psychiatry 2008;69(3):349-57
70. EMEA. Available from: http://eudravigilance.emea.europa.eu/human/ index.asp
71. GlaxoSmithKline. A post-marketing surveillance to monitor the safety of Seroxat (paroxetine hydrochloride) administered in Korean subjects according to the prescribing information. Study No: 29060/516
72. GlaxoSmithKline. Study No: BRL29060A/104228
73. GlaxoSmithKline. Study No.: 29060/650
74. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 2007;68(Suppl 8):26-34
75. Papakostas GI. Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry 2007;68(Suppl 10):11-7
76. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306(6879):683-7
77. Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001;16(3):169-78
78. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158(6):906-12
79. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(Suppl 1):19-26
80. Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005;66(1):94-9
81. Mazeh D, Shahal B, Aviv A, et al. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol 2007;22(6):371-5
82. Allgulander C, Mangano R, Zhang J, et al. Efficacy of Venlafaxine ER in patients with social awdety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19(6):387-96
83. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002;10(5):541-50
84. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61(9):656-63
85. Keene MS, Eaddy MT, Mauch RP, et al. Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs). Curr Med Res Opin 2005;21(10):1651-8